<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01024829</url>
  </required_header>
  <id_info>
    <org_study_id>PET Boost</org_study_id>
    <nct_id>NCT01024829</nct_id>
  </id_info>
  <brief_title>Dose Escalation by Boosting Radiation Dose Within the Primary Tumor Using FDG-PET-CT Scan in Stage IB, II and III NSCLC</brief_title>
  <acronym>PET Boost</acronym>
  <official_title>Dose Escalation by Boosting Radiation Dose Within the Primary Tumor on the Basis of a Pre-treatment FDG-PET-CT Scan in Stage IB, II and III NSCLC: a Randomized Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Union</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increasing (&quot;boosting&quot;) the radiation dose for patients with non-small cell lung carcinoma to
      the individual maximal dose which can safely be given. The question is if patients should
      receive this boost on the whole tumor on part of the tumor. Therefore patients are randomized
      for one of these two treatment options. All patients will receive 24 radiations. Dose
      increasement will be enabled by a so called integrated boost.

      Furthermore:

      - PET imaging of hypoxia using [18F]HX4, single injection and then PET CT scanning two and
      four hours post injection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized phase II study will be conducted in patients with inoperable stage IB, II or III
      non-small cell lung cancer (NSCLC). The patients will be randomized to receive the standard
      66 Gy given in 24 fractions of 2.75 Gy with an integrated boost to the primary tumor as a
      whole (Arm A) or with an integrated boost to the 50% SUVmax area of the primary tumor (of the
      pre-treatment FDG-PET scan) (Arm B). Both treatment arms may be combined with chemotherapy
      (concurrent or sequential). Patients fulfilling the eligibility criteria will be registered
      in the study, and an initial radiotherapy treatment planning will be performed. When an
      integrated boost to the primary tumor as a whole up to 72 Gy is not possible because of dose
      constraints, the patient will receive 66 Gy or lower according to the normal tissue tolerance
      (see below). They will not be randomized, but will be followed in the trial. As such, it will
      be clear which proportion of patients can receive an integrated boost and what the outcome is
      when dose-escalation is not possible.

      Stage IB-II patients receive radiotherapy alone, and stage III patients combined chemotherapy
      and radiation. The patients may have received induction chemotherapy up to two cycles before
      registration in this trial. The statistical calculations have been performed to deal with
      this patient heterogeneity.

      The primary objective of this study is to determine the local progression-free survival
      (LPFS)at 1 year.

      Secondary objectives will be

        -  Toxicity as a function of radiotherapy dose and volume of the tissue irradiated.

        -  Overall survival.

        -  Quality of life

      Furthermore:

        -  PET imaging of hypoxia using [18F]HX4, single injection and then PET CT scanning two and
           four hours post injection.

        -  Dynamic Contrast-Enhanced CT imaging
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Anticipated">November 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Local progression-free survival at 1 year</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Whole tumor boost</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in this arm will receive radiotherapy (66Gy) in 24 fractions of 2.75 Gy with an integrated boost to the primary tumor as a whole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Boost 50% SUV area</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients in this arm receive radiotherapy (66Gy) in 24 fractions of 2.75Gy with an integrated boost to the 50% SUVmax area of the primary tumor (of the pre-treatment FDG-PET-CT scan)</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <description>Radiotherapy</description>
    <arm_group_label>Whole tumor boost</arm_group_label>
    <arm_group_label>Boost 50% SUV area</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients &gt; 18 years with any subtype of pathologically proven (biopsy or cytology),
             non-small cell lung cancer. The diagnosis may be established from biopsy or cytology
             obtained from the primary tumor and/ or from metastatic lymph nodes.

          2. Minimal diameter of the primary tumor 4 cm, this to allow for boosting of sub-volumes.

          3. UICC TNM Stage T2-4, N0-3, M0 disease (TNM definition see appendix 2).

          4. Only stage IB-II patients who are nog candidates for surgery are study candidates.

          5. Measurable disease at registration.

          6. ECOG-performance status ≤ 2 (see appendix 6)

          7. Lung function: FEV1 and DLCO at least 40 % of the age-adjusted normal value

          8. Willing and able to give a written informed consent.

          9. Patients with locoregional recurrent lung tumor following surgery or a second primary
             cancer (at least 3 years after treatment) are eligible, unless a pneumonectomy was
             performed.

         10. SUVmax in the pre-treatment FDG-PET scan ≥ 5 for the primary tumor.

         11. Adequate organ function, including the following:

               -  Adequate bone marrow reserve: absolute neutrophil (segmented and bands) count
                  (ANC) ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, and hemoglobin ≥ 9 g/dL.

               -  Hepatic: bilirubin ≤ 1.5 times the upper limit of normal (x ULN); alkaline
                  phosphatase (AP), aspartate aminotransferase (ASAT), and alanine aminotransferase
                  (ALAT) ≤ 3.0 x ULN (AP, AST, and ALT ≤ 5 x ULN is acceptable if liver has tumor
                  involvement).

               -  Renal: calculated creatinine clearance (CrCl) ≥ 45 ml/min based on the original
                  weight based Cockcroft and Gault formula

         12. For women: Must be surgically sterile, postmenopausal, or compliant with a highly
             reliable contraceptive method (failure rate &lt;1%) during and for 6 months after the
             treatment period; must have a negative serum or urine pregnancy test within 7 days
             before study enrollment and must not be breast-feeding.

         13. For men: Must during chemotherapy take adequate contraceptive measures.

        Exclusion Criteria:

          1. Prior radiotherapy to the thorax.

          2. Clinical superior vena cava syndrome, malignant pleural effusion or malignant
             pericardial effusion.

          3. T4, specified as:Tumor growth in large blood vessels on spiral CT scan or encasement
             &gt;50%

          4. multiple nodules in the same or ipsilateral lobe(s).

          5. Post-obstructive atelectasis or infiltration that cannot be distinguished from tumor
             on a CT-PET scan.

          6. Patients with a diagnosis of other cancer within the last 3-years (except in situ
             carcinoma's and / or non-melanoma skin cancer).

          7. Pregnant women, lactating women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>José Belderbos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NKI-AvL</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jose Belderbos, MD, PhD</last_name>
    <phone>+31 20 512 9111</phone>
    <email>j.belderbos@nki.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dirk De Ruysscher, MD, PhD</last_name>
    <phone>+31 88 44 55 666</phone>
    <email>dirk.deruysscher@maastro.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Leuven, campus Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maarten Lambrecht, MD, PhD</last_name>
      <phone>+ 32 16346902</phone>
      <email>maarten.lambrecht@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Maarten Lambrecht, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gitte Persson, MD, PhD</last_name>
      <phone>+45 35454391</phone>
      <email>Gitte.Persson@regionh.dk</email>
    </contact>
    <investigator>
      <last_name>Gitte persson, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MAASTRO clinic</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 ET</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bart Reymen, MD, PhD</last_name>
      <phone>+31 88 44 55 776</phone>
      <email>bart.reymen@maastro.nl</email>
    </contact>
    <contact_backup>
      <last_name>Dirk de Ruysscher</last_name>
      <phone>+31 88 44 55 776</phone>
      <email>dirk.deruysscher@maastro.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Bart Reymen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NKI/AVL</name>
      <address>
        <city>Amsterdam</city>
        <zip>1066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Belderbos, MD, PhD</last_name>
      <phone>+31 20 512 9111</phone>
      <email>j.belderbos@nki.nl</email>
    </contact>
    <contact_backup>
      <last_name>Judi van Diessen, MD</last_name>
      <phone>+31 20 512 9111</phone>
      <email>j.v.diessen@nki.nl</email>
    </contact_backup>
    <investigator>
      <last_name>José Belderbos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Medical Centre</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edith Dieleman, MD, PhD</last_name>
      <phone>+ 31 20 566 7990</phone>
      <email>e.m.dieleman@amc.uva.nl</email>
    </contact>
    <contact_backup>
      <last_name>Willemijn Kolff, MD</last_name>
      <phone>+ 31 20 566 3433</phone>
      <email>m.w.kolff@amc.uva.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Karolinska Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hedvig Bjorkestrand, MD, PhD</last_name>
      <email>hedvig.bjorkestrand@karolinska.se</email>
    </contact>
    <investigator>
      <last_name>Hedvig Bjorkestrand, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne Faivre-Finn, MD, PhD</last_name>
      <phone>+44(0) 1614468200</phone>
      <email>corinne.finn@christie.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Netherlands</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2009</study_first_submitted>
  <study_first_submitted_qc>December 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2009</study_first_posted>
  <last_update_submitted>January 19, 2017</last_update_submitted>
  <last_update_submitted_qc>January 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non small cell lung cancer</keyword>
  <keyword>Inoperable</keyword>
  <keyword>HX4</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

